Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million

$25 Million Equity Investment by Pfizer at $9.90 Per Share

Term Loan Facility from Hercules Providing Up to $100 Million

If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing transactions. The first is a $25 million equity investment by Pfizer Inc. (NYSE: PFE) at $9.90 per share. The second is a term loan facility providing Akero with access to up to $100 million from Hercules Capital, Inc. (NYSE: HTGC), of which $10 million will be drawn at transaction close. Together with existing cash, proceeds will support Akero's continued development of efruxifermin (EFX), a long-acting analog of fibroblast growth factor 21 (FGF21), including two ongoing Phase 2b clinical trials in patients with pre-cirrhotic and cirrhotic nonalcoholic steatohepatitis (NASH); manufacture of a drug product-device combination for use in Phase 3 clinical trials; and starting a Phase 3 clinical trial program. If the term loan is fully drawn, proceeds from these two transactions together with budget optimization efforts are expected to fund Akero's current operating plan until the third quarter of 2024. This extends Akero's previously announced cash guidance by a full year (from the third quarter of 2023 to the third quarter of 2024), two years beyond the anticipated readout of the HARMONY study in the third quarter of this year.

"Pfizer has deep expertise and history in addressing health challenges that affect millions of patients around the world, including cardiometabolic diseases. We are honored and excited to have their confidence, collaboration and support," said Andrew Cheng, M.D. Ph.D., president and chief executive officer of Akero. "In addition, Hercules Capital has a rich history of investing in innovative biotechnology companies. We are very grateful for their significant partnership and support. With our existing cash on hand, we expect these two financings will extend our cash runway a full two years beyond our upcoming HARMONY readout, providing us the flexibility to optimize our capital structure to support the continued development of EFX."

Pfizer is investing in Akero through the Pfizer Breakthrough Growth Initiative (PBGI), which seeks to support biotechnology companies that share its commitment to delivering transformative therapies for patients in therapeutic areas consistent with Pfizer's core areas of focus. Under the terms of the agreement, Akero has agreed to sell 2,525,252 shares to Pfizer at a price of $9.90 per share, for gross proceeds of $25 million. The shares of common stock were offered and sold to Pfizer in a registered direct offering conducted without an underwriter or placement agent. The offering is expected to close on or about June 17, 2022. Following the transaction, Pfizer will own approximately 6.7% of Akero's outstanding common stock. As part of the transaction, Akero will establish a Scientific Advisory Board, with Pfizer appointing one member. Akero will maintain ownership and control of EFX, the rest of its pipeline, and Akero's operations.

"EFX has quickly emerged as a promising potential NASH therapy, with a strong record of clinical trial data," said Jeff Pfefferkorn, Ph.D., Vice President of Discovery & Development, Internal Medicine Research Unit, Pfizer, who is expected to join Akero's newly formed Scientific Advisory Board. "NASH is a priority therapeutic area for Pfizer due to the substantial global unmet medical need it represents, and we are excited to support Akero as it advances EFX towards a potential Phase 3 study."

The $100 million term loan facility is being provided by Hercules Capital, a leader in customized specialty financing for life science companies. Under the terms of the loan agreement, $10 million will be drawn at closing. An additional $10 million is immediately available to Akero at its sole discretion. Akero may draw an additional $35 million in two separate tranches upon achievement of near-term clinical and financial milestones. An additional $45 million may be drawn in a third tranche, subject to the approval of Hercules Capital. The loan bears an initial interest rate of 7.65% and adjusts with future changes in the prime rate. Akero will pay interest only for the first 24 months, extendable to 36 months on achievement of certain milestones. The loan matures 54 months from closing in December 2026. "We believe there is tremendous patient and clinical value in financing the development of potentially innovative treatments for NASH," said Cristy Barnes, Managing Director at Hercules Capital. "We're excited to support Akero – both now and in the future – in its continued clinical development of EFX for the treatment of advanced NASH."

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Akero is headquartered in South San Francisco. Visit www.akerotx.com for more information.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding the Company's cash runway, including its extension to the third quarter of 2024, statements about the completion and timing of the registered offering of the Company's common stock to Pfizer Inc., the Company's business plans and objectives, including future plans or expectations for EFX, upcoming milestones, and therapeutic effects of EFX, as well as the dosing, safety and tolerability of EFX; conduct of the Company's Phase 2b HARMONY study, including expected timing to report results; conduct of the Company's Phase 2b SYMMETRY study, including expected timing to complete enrollment and report results; the timely availability of new drug substance and a new combination drug product-device to support Phase 3 clinical trials; expectations regarding the Company's use of capital, expenses and other future financial results and the potential impact of COVID-19 on strategy, future operations, manufacturing, and clinical trial enrollment and data collection. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the impact of COVID-19 on the Company's ongoing and future operations, including potential negative impacts on the Company's employees, third-parties, manufacturers, supply chain and production as well as on global economies and financial markets; the success, cost, and timing of the Company's product candidate development activities and planned clinical trials; the Company's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; the Company's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in the Company's other filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
Christina Tartaglia
212.362.1200
IR@akerotx.com

Media Contact:
650.487.6488
media@akerotx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

PFE
Lahontan Gold Corp.

Lahontan Gold Corp. Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Lahontan Gold Corp. (TSXV:LG)

Lahontan Gold Corp.

Overview

Lahontan Gold (TSXV:LG,OTCQB LGCXF) is advancing a portfolio of 100 percent-controlled gold and silver assets in Nevada’s Walker Lane, led by the Santa Fe Mine, a past-producing open-pit heap leach operation. The company has expanded the mineral resource and is now advancing permitting and technical studies to support the project’s development. Management is driving multiple technical workstreams simultaneously, spanning state and federal permitting, metallurgical optimizations via an on-site laboratory, and engineering studies to support its upcoming production restart.

Lahontan Gold drilling exploration rig set up

An updated NI 43-101 Mineral Resource Estimate has been completed, showing an overall 22 percent increase from the 2024 MRE. The project now hosts indicated mineral resources of 31.15 Mt grading 0.99 g/t gold equivalent, totaling 993,000 gold equivalent ounces and inferred mineral resources of 41.60 Mt grading 0.71 g/t gold equivalent, totaling 954,000 gold equivalent ounces. That estimate fed directly into the updated PEA announced in October, which outlines an 11-year mine life and average annual production of about 91,900 gold-equivalent ounces.

The company is now focused on filing the supporting technical report and submitting the final Mine Plan of Operations to the U.S. Bureau of Land Management. Construction permits are expected in 2027.

Value creation is supported by aggressive, multi-rig exploration campaigns designed to scale the resource base rapidly. The 2026 campaign deploys a three-pronged approach: a 10,000-metre Reverse Circulation program chasing new exploration targets, a 2,023-metre core drilling program to finalize mine permitting data, and a 1,740-metre sonic program executing 96 drill holes into historic heap leach pads to add low-cost ounces directly to the mine life.

The execution of this corporate strategy is guided by a founder-led management team and an independent board with deep operational histories in the Great Basin. This leadership capability is validated by a corporate share structure that features 41 percent institutional ownership—including resource funds like MERK, EMA (Larry Lepard), APAC, and PALOS—alongside 6 percent insider ownership.

Note: Mineral resources are not mineral reserves and do not demonstrate economic viability.

Company Highlights

  • District-scale Nevada Portfolio: Lahontan Gold is advancing a portfolio of 100 percent-controlled gold and silver projects in Nevada’s Walker Lane, anchored by the Santa Fe Mine and complemented by the West Santa Fe and Moho projects.
  • Flagship Brownfields Development: The Santa Fe Mine is a past-producing open-pit heap leach gold and silver operation that produced approximately 359,202 ounces of gold and 702,067 ounces of silver between 1988 and 1994.
  • Large Mineral Resource: The Santa Fe mine project hosts a pit-constrained indicated mineral resource of 1,195,000 contained gold equivalent ounces grading 0.78 grams per tonne gold equivalent, and inferred mineral resources of 1,190,000 contained gold equivalent ounces grading 0.61 grams per tonne gold equivalent. Its updated MRE shows a 435,000-ounce, or 22 percent, increase from its 2024 MRE.
  • Robust Project Economics: An updated 2026 Preliminary Economic Assessment (PEA) shows a post-tax NPV of US$820 million and a 40.1 percent IRR over an 11-year mine life, based on gold and silver prices of US$3,600 per ounce and US$49 per ounce, respectively.
  • Established Infrastructure: Santa Fe benefits from infrastructure including year-round access, an active substation on site, access to four water wells, and property power lines.
  • Top Rated Mining Jurisdiction: Nevada is the world’s top-rated mining jurisdiction as ranked by the 2025 Fraser Institute Survey, featuring straightforward permitting.

Key Projects

Santa Fe Mine (Flagship Brownfields Asset)

Map of Lahontan Gold project location with neighboring projects and owners

The Santa Fe Mine is Lahontan’s flagship, 100 percent-controlled gold and silver project located in Nevada’s Walker Lane. Covering a district-scale land package of more than 28 square kilometres, the past-producing open-pit heap leach operation produced 359,202 ounces of gold and 702,067 ounces of silver between 1988 and 1994.

Current resource modeling shows substantial gold oxide mineralization remaining directly within the high-wall and pit bottoms, which feature highly competent wall rock and stable 50-degree pit slopes. The company completed an updated Mineral Resource Estimate for the project in August 2026, showing an overall 22 percent increase from the 2024 MRE. The project now hosts indicated mineral resources of 31.15 Mt grading 0.99 g/t gold equivalent totaling 993,000 gold equivalent ounces and inferred mineral resources of 41.60 Mt grading 0.71 g/t gold equivalent totaling 954,000 gold equivalent ounces.

The updated resource estimate also includes an indicated oxide and transitional resource of 15.9 million tonnes grading 0.57 g/t gold, alongside 15.2 million tonnes of indicated sulfide grading 1.24 g/t gold.

Lahontan Gold's drill hole location and geology map of the Santa Fe Mine project

Recent drilling has successfully demonstrated that the resource base remains open for depth and strike expansion. Deep core drilling beneath the conceptual pit boundaries at the Calvada deposit intercepted 90.8 metres grading 0.44 g/t gold equivalent oxide, confirming significant down-dip expansion potential. Simultaneously, 2026 step-out exploration drilling discovered a brand-new gold zone called West Slab, yielding unconstrained structural intercepts of 35.0 metres grading 0.34 g/t gold equivalent and 61.0 metres grading 0.26 g/t gold equivalent.

An updated PEA for Santa Fe outlined an 11-year mine life and a post-tax NPV of US$820 million at base-case prices of US$3,600/oz gold and US$49/oz silver. The study estimates a 40.1 percent IRR and US$1.32 billion in after-tax life-of-mine net cash flow.

Average annual production is projected at about 91,900 gold-equivalent ounces, increasing to about 112,500 in years four to eleven. Estimated gold cash costs are US$1,909/oz and AISC is US$2,250/oz. Pre-production capital is US$172 million, with a projected payback of 3.7 years. The capital cost estimate in the PEA update includes a 20 percent contingency.

Note: Mineral resources are not mineral reserves and do not demonstrate economic viability.

West Santa Fe (Satellite Oxide Asset)

West Santa Fe is a satellite project located just 13 kilometres west of the main Santa Fe Mine infrastructure, encompassing a 19 square kilometre land package. The asset features gold and silver mineralization starting directly at surface and has the potential to host a significant shallow oxide gold and silver resource.

Recent twin-hole drilling has confirmed the validity of the historical database while delivering exceptional grades. Reverse Circulation hole WSF25-04R hit 36.6 metres grading 3.11 g/t gold equivalent from the surface, including a high-grade zone of 10.7 metres grading 5.75 g/t gold equivalent in completely oxidized material. Metallurgical testing highlights excellent processing characteristics; historic column leach tests showed 70 percent gold and 50 percent silver recoveries, while recent cyanide-extractable assay results outperformed expectations with an average gold recovery of 81 percent and silver recovery of 60 percent. Because the deposit aligns structurally as a look-alike to the main Santa Fe pit, it is being designed as a low-cost, open-pit satellite operation that can feed directly into the flagship processing hub.

Moho Mine (Satellite High-Grade Asset)

The Moho Mine represents a satellite high-grade gold and silver asset within Lahontan’s regional Walker Lane portfolio. Characterized by an extensive multiple-vein system, the historic underground asset features historic mining grades of 25 g/t gold and 300 g/t silver. It provides the company with localized, high-grade exploration targets that run parallel to its primary large-scale gold oxide heap-leach development projects.

Management Team

Kimberly Ann – Founder, Executive Chair, President and CEO

Kimberly Ann has more than a decade of experience founding and financing junior resource companies, raising more than US$300 million in capital and participating in multiple mergers, acquisitions and corporate transactions in the mining sector. She has also raised more than US$210 million in project financing and participated in three M&A transactions. Previously, she led Prodigy Gold through its $340 million acquisition by Argonaut Gold, held senior roles at Waterton Global Resource Management and helped bring PPX Mining's Callanquitas gold-silver mine into production in Peru. She is currently a Managing Partner of KA Gold LLC.

Brian Maher – Founder, Senior Vice President - Mine Development & Exploration

Brian Maher is a certified professional geologist. He previously served as President and CEO of Prodigy Gold, guiding exploration and development of the Magino deposit through the company's $341 million acquisition. His career includes sixteen years with ASARCO and senior exploration roles with Metallic Ventures Gold and Hochschild Mining.

Tony Gesualdo — Vice President, Exploration

Tony Gesualdo is a structural and economic geologist focusing on early-stage exploration, resource development, open-pit expansion and underground production geology. He previously worked as Senior Exploration Geologist at McEwen Inc., and also held roles in companies such as Coeur Mining, OceanaGold and Barrick Gold. He is the former Exploration Manager at Lahontan Gold and was instrumental to the development of the initial MRE at Santa Fe.

Billy Choi – Chief Financial Officer

Billy Choi holds extensive experience in public-company finance, capital markets, and transaction management. His background includes financial reporting and prospectus readiness, strengthening internal controls and financial processes, and helping build finance infrastructure for resource companies. He recently served as Vice President of Finance at Lithium Royalty Corp, where he played a significant role in the company’s public trading activities.

Chris Irwin - Corporate Secretary

Chris Irwin is a securities and corporate-commercial lawyer for public companies, boards and independent committees. He has served as a director and officer for numerous businesses such as those acquired by IAMGOLD, Goldcorp and First Majestic Silver. He is currently a Managing Partner of Irwin Lowy LLP.

Jen Earle - Investor Relations and Business Development

Jen brings two decades of experience in the natural resources sector, with extensive expertise in investor relations, capital markets, and strategic investor engagement for companies listed on the LSE, ASX and TSX. Her career spans junior mining companies with assets across multiple jurisdictions and a FTSE 250 oil and gas company, giving her broad experience across the natural resource and international capital markets landscape. Throughout her career, she has led and delivered capital market days, international field programs and global roadshows, developing meaningful relationships with investors and helping companies effectively communicate their strategy, assets and growth opportunities to the market.

Board of Directors

Miranda Werstiuk – Independent Director

Miranda Werstiuk holds over 30 years of experience across global resource markets, specializing in equity, debt and alternative financing for natural-resource, technology and renewable-energy companies. She currently serves on the board of Guanajuato Silver Company and is active in the PDAC, CIM and Women in Mining.

Shane Williams – Independent Director

Shane Williams is CEO and President of West Red Lake Gold Mines and previously served as COO of Skeena Resources. At Eldorado Gold, he led the Lamaque project from PEA to commercial operation in 18 months. His career also includes open-pit project roles with Rio Tinto and Kaunis Iron.

Evan Pelletier – Independent Director

Evan Pelletier has over 30 years of underground operating and project-delivery experience.

His career includes senior roles with Americas Gold & Silver and Kirkland Lake Gold, where he served at the Macassa mine during a period of significant growth. His international experience spans Mongolia, Argentina and Africa, including the oversight of a 2,000-metre shaft project delivered on time and on budget.

Antony Rowe - Independent Director

Antony Rowe is a mining-finance executive experienced in private credit, project finance, corporate lending and law. He previously helped build Resource Capital Funds' mining debt and credit strategy and executed mining investments at Investec Bank across Europe, the Americas and Africa. He currently serves as a Managing Director of Arrowpoint Mining Capital and Senior Adviser to Canmore Capital.

Note: CEO Kimberly Ann also forms part of Lahontan Gold’s board of directors.

Arvinas and Pfizer Announce Upcoming Vepdegestrant  Poster Presentations at the 2023 European Society for Medical Oncology  Breast Cancer Annual Congress

Arvinas and Pfizer Announce Upcoming Vepdegestrant Poster Presentations at the 2023 European Society for Medical Oncology Breast Cancer Annual Congress

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Vepdegestrant is a novel investigational PROTAC ® estrogen receptor... Keep Reading...
Pfizer Reports First-Quarter 2023 Results

Pfizer Reports First-Quarter 2023 Results

First-Quarter 2023 Revenues of $18.3 Billion Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1 Billion Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew... Keep Reading...
XTANDI®  plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

XTANDI® plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Results show the potential for XTANDI to add to the standard of care in prostate cancer, if approved Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki... Keep Reading...
U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

PREVNAR 20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine, helping to protect against all 20 serotypes contained in the vaccine PREVNAR 20 builds on PREVNAR 13 ® and includes seven additional serotypes shown to be associated with antibiotic resistance,... Keep Reading...
Pfizer Declares Second-Quarter 2023 Dividend

Pfizer Declares Second-Quarter 2023 Dividend

Board of Directors approves quarterly cash dividend of $0.41 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company's common stock, payable June 9, 2023, to holders of the Common Stock of record at the close of... Keep Reading...
Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), a drug discovery company developing novel therapeutics for autism spectrum disorder ("ASD") and related neurodevelopmental disorders, is... Keep Reading...
Medical professional's hand under a digital interface with a glowing cross and circuit design.

Eli Lilly Brings AI to Drug Delivery in METiS TechBio Deal

METiS TechBio (HKEX:7666) could collect up to US$1.1 billion in milestone payments from Eli Lilly and Company (NYSE:LLY) under a new research pact to design lipid nanoparticles that carry medicines to specific tissues in the body.Lipid nanoparticles, or LNPs, carry therapeutic payloads to target... Keep Reading...
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), today announced that four... Keep Reading...
Two people wearing lab coats shake hands in business agreement.

Telix Acquires Germany's ITM in US$1.65 Billion Deal

Melbourne-based Telix Pharmaceuticals (ASX:TLX) has agreed to acquire Germany’s ITM Isotope Technologies to secure commercial-scale radioisotope manufacturing and expand into neuroendocrine tumor treatments.The deal brings ITM’s global radioisotope production and distribution network spanning... Keep Reading...
Data Safety Monitoring Board  Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy... Keep Reading...
Lahontan Gold Corp.

Lahontan Gold Corp. Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News